Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 2 completion78d agoBuddhachinaraj Hospital — dexamethasone (Phase II Trial Completion)dexamethasone

Therapy area: Musculoskeletal Disorders. Indication: Bone Fracture

full page →dexamethasone →source: globaldata

Apr 30, 2026phase 2 completion78d agoHuadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)LIDOCAINE

Therapy area: Respiratory. Indication: Cough

full page →LIDOCAINE →source: globaldata

Apr 30, 2026phase 2 completion78d agoChongqing Medical University Hospital 2 — propofol (Phase II Trial Completion)PROPOFOL

Therapy area: Central Nervous System. Indication: Cognitive Disorders

full page →PROPOFOL →source: globaldata

Apr 30, 2026phase 2 completion78d agoHematology Hospital of Chinese Academy of Medical Sciences — letermovir (Phase II Trial Completion)letermovir

Therapy area: Undisclosed. Indication: Unspecified

full page →letermovir →source: globaldata

Apr 30, 2026phase 2 completion78d agoCantonal Hospital Authority — bupivacaine (Phase II Trial Completion)bupivacaine

Therapy area: Central Nervous System. Indication: Post-Operative Pain

full page →bupivacaine →source: globaldata

Apr 30, 2026phase 2 completion78d agoInstituto de Investigacion sanitaria de Santiago de Compostela — Vacucis (Phase II Trial Completion)Vacucis

Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Candidiasis, Xerostomia

full page →Vacucis →source: globaldata

Apr 30, 2026phase 2 completion78d agoArcus Biosciences Inc — atezolizumab (Phase II Trial Completion)atezolizumab

Therapy area: Oncology. Indication: Prostate Cancer

full page →atezolizumab →source: globaldata

Apr 30, 2026phase 2 completion78d agoNoster Inc — 10-hydroxy-cis-12- octadecenoic acid (Phase II Trial Completion)10-hydroxy-cis-12- octadecenoic acid

Therapy area: Metabolic Disorders. Indication: Type 1 Diabetes (Juvenile Diabetes)

full page →10-hydroxy-cis-12- octadecenoic acid →source: globaldata

Apr 30, 2026phase 2 completion78d agoHospital Of Dalian Medical University 1 — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 2 completion78d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — capecitabine (Phase II Trial Completion)capecitabine

Therapy area: Oncology. Indication: Colorectal Cancer

full page →capecitabine →source: globaldata

Apr 30, 2026phase 2 completion78d agoNanfang Hospital of Southern Medical University — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Small-Cell Lung Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 2 completion78d agoLifeArc — fecal microbiota (Phase II Trial Completion)fecal microbiota

Therapy area: Gastrointestinal. Indication: Inflammatory Bowel Disease, Primary Sclerosing Cholangitis

full page →fecal microbiota →source: globaldata

Apr 30, 2026phase 2 completion78d agoNational Cheng-Kung University Hospital — SynPro-15G (Phase II Trial Completion)SynPro-15G

Therapy area: Gastrointestinal. Indication: Irritable Bowel Syndrome

full page →SynPro-15G →source: globaldata

Apr 30, 2026phase 2 completion78d agoPolice General Hospital — acetaminophen (Phase II Trial Completion)acetaminophen ER

Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

full page →acetaminophen ER →source: globaldata

Apr 30, 2026phase 2 completion78d agoEmory University — (carbidopa + levodopa) (Phase II Trial Completion)(carbidopa + levodopa)

Therapy area: Central Nervous System. Indication: Cognitive Disorders, Depression

full page →(carbidopa + levodopa) →source: globaldata

Apr 30, 20268k filing78d ago$HCWB — HCW Biologics Inc. (HCWB) — 8-K filing

Items: 8.01, 9.01

Week of Apr 27, 2026